A Phase III Study of AK104 as Adjuvant Therapy in HCC With High Risk of Recurrence After Curative Resection

This study is testing a drug called AK104 — an immunotherapy that activates the immune system to fight cancer — as a treatment after surgery in patients with liver cancer (hepatocellular carcinoma, HCC) who are at high risk of the cancer coming back. **You may be eligible if...** - You have been diagnosed with liver cancer (HCC) confirmed by tissue biopsy - You had a complete surgical removal of your cancer with no remaining tumor - You have at least one risk factor for cancer recurrence after surgery - Your liver function is good (Child-Pugh grade A) and you feel well (ECOG score 0) - Your underlying liver disease (such as hepatitis) is under control **You may NOT be eligible if...** - You have a rare type of liver cancer (such as fibrolamellar or sarcoma-like HCC, or cholangiocarcinoma) - You had cancer treatments other than surgery before enrollment - You have poor liver function, active infection, bleeding risks, or uncontrolled high blood pressure or heart problems - You have active autoimmune disease or a history of organ transplant - You are pregnant Talk to your doctor to see if this trial is right for you.